Skip to main content

Table 2 Subgroup analyses for the association between PS and the survival

From: Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis

Subgroup analysis OS PFS
No. of studies Pooled HR (95% CI) P value Heterogeneity No. of studies Pooled HR (95% CI) P value Heterogeneity
I2 (%) P I2 (%) P
Overall 17 2.08 (1.78–2.45) <  0.00001 8 0.36 8 1.51 (1.20–1.91) 0.0005 25 0.23
Type of PS scale
 KPS 6 2.20 (1.65–2.94) <  0.00001 24 0.26 5 1.74 (1.19–2.56) 0.005 0 0.50
 ECOG PS 11 2.03 (1.68–2.46) <  0.00001 6 0.39 3 1.39 (1.04–1.87) 0.03 61 0.08
Study setting
 Asia 6 2.25 (1.71–2.95) <  0.00001 26 0.24 4 1.73 (1.14–2.64) 0.01 11 0.34
 Europe 8 1.95 (1.56–2.43) <  0.00001 28 0.20 4 1.42 (1.08–1.88) 0.01 44 0.15
 America 3 2.25 (1.43–3.53) 0.0005 0 0.93 0
Year of publication
 Before 2015 11 1.79 (1.44–2.22) <  0.00001 17 0.28 6 1.51 (1.18–1.94) 0.001 44 0.11
 After 2015 6 2.49 (1.97–3.15) <  0.00001 0 0.95 2 1.50 (0.73–3.07) 0.27 0 0.56
NOS score
 6 5 2.07 (1.57–2.74) <  0.00001 28 0.24 2 0.90 (0.54–1.50) 0.67 40 0.20
 7 7 1.80 (1.40–2.32) <  0.00001 19 0.29 4 1.57 (1.18–2.10) 0.002 0 0.92
 8 5 2.61 (1.92–3.55) <  0.00001 0 0.90 2 2.43 (1.36–4.33) 0.003 0 0.43
  1. OS overall survival, PFS progression-free survival, PS performance status, KPS Karnofsky performance status, ECOG PS Eastern Cooperative Oncology Group performance status, NOS Newcastle-Ottawa score, CI confidence interval